[{"id":"61d56240-acd7-4036-be44-40ad727ab77a","acronym":"A051701","url":"https://clinicaltrials.gov/study/NCT03984448","created_at":"2021-01-18T19:35:47.901Z","updated_at":"2025-02-25T15:11:12.787Z","phase":"Phase 2/3","brief_title":"Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas","source_id_and_acronym":"NCT03984448 - A051701","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" MYC • BCL2 • BCL6","pipe":" | ","alterations":" BCL2 expression • MYC expression • MYC translocation • MYC negative • BCL2 translocation","tags":["MYC • BCL2 • BCL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCL2 expression • MYC expression • MYC translocation • MYC negative • BCL2 translocation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • vincristine • prednisone • Truxima (rituximab-abbs) • Riabni (rituximab-arrx) • Delito (rituximab biosimilar) • GB241 (rituximab biosimilar) • JHL1101 (rituximab biosimilar) • Mabtas (rituximab biosimilar) • Novex (rituximab biosimilar) • SIBP-02 (rituximab biosimilar) • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 363","initiation":"Initiation: 10/22/2019","start_date":" 10/22/2019","primary_txt":" Primary completion: 04/01/2028","primary_completion_date":" 04/01/2028","study_txt":" Completion: 04/01/2028","study_completion_date":" 04/01/2028","last_update_posted":"2025-02-13"},{"id":"302e12e8-3d06-4205-8871-3fc4c45bd55f","acronym":"","url":"https://clinicaltrials.gov/study/NCT01856192","created_at":"2021-01-18T08:17:29.922Z","updated_at":"2025-02-25T16:43:43.231Z","phase":"Phase 2","brief_title":"Rituximab and Combination Chemotherapy With or Without Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Diffuse Large B Cell Lymphoma","source_id_and_acronym":"NCT01856192","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" ALK • MYC • CD20 • CD4","pipe":" | ","alterations":" CD20 expression • MYC translocation","tags":["ALK • MYC • CD20 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 expression • MYC translocation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • lenalidomide • doxorubicin hydrochloride • cyclophosphamide • vincristine • prednisone • Truxima (rituximab-abbs) • Riabni (rituximab-arrx) • Delito (rituximab biosimilar) • GB241 (rituximab biosimilar) • JHL1101 (rituximab biosimilar) • Mabtas (rituximab biosimilar) • Novex (rituximab biosimilar) • SIBP-02 (rituximab biosimilar) • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 349","initiation":"Initiation: 08/27/2013","start_date":" 08/27/2013","primary_txt":" Primary completion: 03/26/2020","primary_completion_date":" 03/26/2020","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2025-02-06"},{"id":"51bc21f1-64c8-4e95-bcfa-4fdd977e48c0","acronym":"","url":"https://clinicaltrials.gov/study/NCT04572763","created_at":"2021-01-18T21:50:00.501Z","updated_at":"2025-02-25T17:24:50.909Z","phase":"Phase 1/2","brief_title":"Copanlisib Plus Venetoclax in R/R DLBCL","source_id_and_acronym":"NCT04572763","lead_sponsor":"Dana-Farber Cancer Institute","biomarkers":" BCL2 • BCL6","pipe":" | ","alterations":" MYC translocation","tags":["BCL2 • BCL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MYC translocation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • Aliqopa (copanlisib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 48","initiation":"Initiation: 09/08/2021","start_date":" 09/08/2021","primary_txt":" Primary completion: 06/01/2025","primary_completion_date":" 06/01/2025","study_txt":" Completion: 09/01/2025","study_completion_date":" 09/01/2025","last_update_posted":"2024-12-20"},{"id":"db5fc24c-f27b-49ea-89fd-c21be640542e","acronym":"","url":"https://clinicaltrials.gov/study/NCT03311958","created_at":"2021-01-18T16:21:30.638Z","updated_at":"2024-07-02T16:34:59.289Z","phase":"Phase 1","brief_title":"Molecular Monitoring With Circulating Tumor DNA and Nivolumab Maintenance","source_id_and_acronym":"NCT03311958","lead_sponsor":"Fox Chase Cancer Center","biomarkers":" MYC","pipe":" | ","alterations":" MYC translocation","tags":["MYC"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MYC translocation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 15","initiation":"Initiation: 05/15/2018","start_date":" 05/15/2018","primary_txt":" Primary completion: 01/26/2024","primary_completion_date":" 01/26/2024","study_txt":" Completion: 12/15/2024","study_completion_date":" 12/15/2024","last_update_posted":"2024-06-04"},{"id":"fae84839-338f-451e-a552-ea4530e69d00","acronym":"UKALL14","url":"https://clinicaltrials.gov/study/NCT01085617","created_at":"2021-01-18T04:16:52.338Z","updated_at":"2024-07-02T16:35:04.439Z","phase":"Phase 3","brief_title":"Standard Chemotherapy With or Without Nelarabine or Rituximab in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia","source_id_and_acronym":"NCT01085617 - UKALL14","lead_sponsor":"University College, London","biomarkers":" ABL1 • BCR • MYC","pipe":" | ","alterations":" MYC translocation • Chr t(4;11)(q21;q23)","tags":["ABL1 • BCR • MYC"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MYC translocation • Chr t(4;11)(q21;q23)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • imatinib • cytarabine • cyclophosphamide • etoposide IV • vincristine • daunorubicin • melphalan • Oncaspar liquid (pegaspargase) • fludarabine IV • nelarabine • mercaptopurine • Kepivance (palifermin)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 1033","initiation":"Initiation: 12/01/2010","start_date":" 12/01/2010","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2024-05-10"},{"id":"6b069ddb-3d44-4c51-aafc-c9dbf27dc3ef","acronym":"AALL0433","url":"https://clinicaltrials.gov/study/NCT00381680","created_at":"2021-01-18T01:19:36.490Z","updated_at":"2024-07-02T16:35:12.895Z","phase":"Phase 3","brief_title":"Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia","source_id_and_acronym":"NCT00381680 - AALL0433","lead_sponsor":"Children's Oncology Group","biomarkers":" MYC","pipe":" | ","alterations":" MYC translocation","tags":["MYC"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MYC translocation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • vincristine • prednisone • leucovorin calcium • Oncaspar liquid (pegaspargase) • mercaptopurine delayed release (DR6MP) • mercaptopurine • Kidrolase (L-asparaginase) • Neupogen (filgrastim) • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 275","initiation":"Initiation: 03/01/2007","start_date":" 03/01/2007","primary_txt":" Primary completion: 03/01/2016","primary_completion_date":" 03/01/2016","study_txt":"","study_completion_date":"","last_update_posted":"2024-03-26"},{"id":"6a54e9ca-ab14-4985-b527-5f222345e52f","acronym":"","url":"https://clinicaltrials.gov/study/NCT04307576","created_at":"2021-01-18T20:53:16.021Z","updated_at":"2024-07-02T16:35:14.109Z","phase":"Phase 3","brief_title":"A Treatment Study Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia","source_id_and_acronym":"NCT04307576","lead_sponsor":"Mats Heyman","biomarkers":" MYC • BCL2 • KMT2A","pipe":" | ","alterations":" MYC rearrangement + BCL2 rearrangement • MLL rearrangement • MYC rearrangement • MYC translocation • BCL2 rearrangement","tags":["MYC • BCL2 • KMT2A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MYC rearrangement + BCL2 rearrangement • MLL rearrangement • MYC rearrangement • MYC translocation • BCL2 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e imatinib • doxorubicin hydrochloride • Blincyto (blinatumomab) • Besponsa (inotuzumab ozogamicin) • vincristine • thioguanine"],"overall_status":"Recruiting","enrollment":" Enrollment 6430","initiation":"Initiation: 07/13/2020","start_date":" 07/13/2020","primary_txt":" Primary completion: 06/30/2027","primary_completion_date":" 06/30/2027","study_txt":" Completion: 06/30/2032","study_completion_date":" 06/30/2032","last_update_posted":"2024-03-19"},{"id":"145fc814-0727-4779-a567-acfbf6720fd9","acronym":"SAKK 38/23","url":"https://clinicaltrials.gov/study/NCT06090162","created_at":"2023-10-19T17:12:55.572Z","updated_at":"2024-07-02T16:35:14.707Z","phase":"","brief_title":"LIBERTY: Liquid Biopsy to Diagnose and Monitor CNS Involvement in High-risk B Cell Non-Hodgkin Lymphoma","source_id_and_acronym":"NCT06090162 - SAKK 38/23","lead_sponsor":"Swiss Group for Clinical Cancer Research","biomarkers":" TP53 • MYC • BCL2 • BCL6","pipe":" | ","alterations":" TP53 mutation • MYC translocation • BCL2 translocation","tags":["TP53 • MYC • BCL2 • BCL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • MYC translocation • BCL2 translocation"],"overall_status":"Recruiting","enrollment":" Enrollment 64","initiation":"Initiation: 03/12/2024","start_date":" 03/12/2024","primary_txt":" Primary completion: 12/01/2026","primary_completion_date":" 12/01/2026","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2024-03-15"},{"id":"65986e74-a9bc-495d-9648-8e352d126636","acronym":"","url":"https://clinicaltrials.gov/study/NCT05828589","created_at":"2023-04-25T14:03:41.618Z","updated_at":"2024-07-02T16:35:14.643Z","phase":"Phase 1","brief_title":"A Study of BGB-21447, a Bcl-2 Inhibitor, in Mature B-Cell Malignancies","source_id_and_acronym":"NCT05828589","lead_sponsor":"BeiGene","biomarkers":" BCL2","pipe":" | ","alterations":" MYC translocation","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MYC translocation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BGB-21447"],"overall_status":"Recruiting","enrollment":" Enrollment 85","initiation":"Initiation: 06/20/2023","start_date":" 06/20/2023","primary_txt":" Primary completion: 03/01/2026","primary_completion_date":" 03/01/2026","study_txt":" Completion: 10/01/2026","study_completion_date":" 10/01/2026","last_update_posted":"2024-03-15"},{"id":"69353146-1df5-48d8-b94c-7555527cfb6e","acronym":"","url":"https://clinicaltrials.gov/study/NCT05800366","created_at":"2023-04-05T14:03:39.999Z","updated_at":"2024-07-02T16:35:17.942Z","phase":"Phase 2","brief_title":"A Phase II Study of Glofitamab Plus Polatuzumab-R-CHP for Patients With High-risk Diffuse Large B-cell Lymphoma","source_id_and_acronym":"NCT05800366","lead_sponsor":"Jennifer Crombie, MD","biomarkers":" ALK • BCL2 • CD20 • BCL6","pipe":" | ","alterations":" ALK positive • CD20 positive • MYC translocation","tags":["ALK • BCL2 • CD20 • BCL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK positive • CD20 positive • MYC translocation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • prednisone • Polivy (polatuzumab vedotin-piiq) • Columvi (glofitamab-gxbm)"],"overall_status":"Recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 04/06/2023","start_date":" 04/06/2023","primary_txt":" Primary completion: 09/15/2026","primary_completion_date":" 09/15/2026","study_txt":" Completion: 09/15/2029","study_completion_date":" 09/15/2029","last_update_posted":"2024-02-23"},{"id":"300dc214-2f53-46f4-88db-099cbeecb27f","acronym":"","url":"https://clinicaltrials.gov/study/NCT05755087","created_at":"2023-03-06T15:01:37.165Z","updated_at":"2024-07-02T16:35:24.905Z","phase":"Phase 1","brief_title":"Tegavivint for Treating Patients With Relapsed or Refractory Large B-Cell Lymphoma","source_id_and_acronym":"NCT05755087","lead_sponsor":"Lapo Alinari","biomarkers":" MYC • BCL2 • BCL6","pipe":" | ","alterations":" BCL2 expression • MYC expression • MYC translocation • MYC translocation + BCL2 translocation • BCL2 translocation","tags":["MYC • BCL2 • BCL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCL2 expression • MYC expression • MYC translocation • MYC translocation + BCL2 translocation • BCL2 translocation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e tegavivint (BC2059)"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 03/06/2023","start_date":" 03/06/2023","primary_txt":" Primary completion: 03/05/2027","primary_completion_date":" 03/05/2027","study_txt":" Completion: 03/05/2027","study_completion_date":" 03/05/2027","last_update_posted":"2023-12-29"},{"id":"b77bf75c-b84b-4373-9687-867a97189f17","acronym":"","url":"https://clinicaltrials.gov/study/NCT00003838","created_at":"2021-01-17T22:53:23.367Z","updated_at":"2024-07-02T16:35:36.368Z","phase":"Phase 2","brief_title":"Specialized Blood Cell Transplants for Cancers of the Blood and Bone Marrow","source_id_and_acronym":"NCT00003838","lead_sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","biomarkers":" MYC • BCL2 • CD34","pipe":" | ","alterations":" MYC translocation","tags":["MYC • BCL2 • CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MYC translocation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • cyclosporine"],"overall_status":"Completed","enrollment":" Enrollment 202","initiation":"Initiation: 04/15/1999","start_date":" 04/15/1999","primary_txt":" Primary completion: 12/14/2018","primary_completion_date":" 12/14/2018","study_txt":" Completion: 06/18/2020","study_completion_date":" 06/18/2020","last_update_posted":"2023-09-21"},{"id":"382c9498-ae64-48ce-a05f-dcf78ea1d165","acronym":"","url":"https://clinicaltrials.gov/study/NCT03997968","created_at":"2021-08-12T18:53:32.634Z","updated_at":"2024-07-02T16:35:42.822Z","phase":"Phase 1/2","brief_title":"A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors","source_id_and_acronym":"NCT03997968","lead_sponsor":"Cyteir Therapeutics, Inc.","biomarkers":" ER • PGR • MYC • BCL2","pipe":" | ","alterations":" HER-2 positive • HER-2 negative • ER negative • ER positive + PGR positive • PGR positive • MYC translocation • PGR negative","tags":["ER • PGR • MYC • BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 negative • ER negative • ER positive + PGR positive • PGR positive • MYC translocation • PGR negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • Rituxan (rituximab) • capecitabine • bendamustine • CYT-0851"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 170","initiation":"Initiation: 10/09/2019","start_date":" 10/09/2019","primary_txt":" Primary completion: 07/30/2024","primary_completion_date":" 07/30/2024","study_txt":" Completion: 12/30/2024","study_completion_date":" 12/30/2024","last_update_posted":"2023-07-17"},{"id":"e28d1c87-3d40-485a-b890-0ee69359a623","acronym":"V+DA-EPOCH-R","url":"https://clinicaltrials.gov/study/NCT03036904","created_at":"2021-01-18T14:56:53.499Z","updated_at":"2024-07-02T16:36:04.970Z","phase":"Phase 1","brief_title":"Study of Venetoclax Plus DA-EPOCH-R for the Treatment of Aggressive B-Cell Lymphomas","source_id_and_acronym":"NCT03036904 - V+DA-EPOCH-R","lead_sponsor":"Weill Medical College of Cornell University","biomarkers":" BCL2 • BCL6","pipe":" | ","alterations":" MYC translocation","tags":["BCL2 • BCL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MYC translocation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • vincristine • prednisone • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 31","initiation":"Initiation: 02/06/2017","start_date":" 02/06/2017","primary_txt":" Primary completion: 11/11/2021","primary_completion_date":" 11/11/2021","study_txt":" Completion: 11/11/2021","study_completion_date":" 11/11/2021","last_update_posted":"2022-08-24"},{"id":"a15f3c21-a490-40cc-93c8-4d2c83593905","acronym":"","url":"https://clinicaltrials.gov/study/NCT05290337","created_at":"2022-03-22T12:52:47.199Z","updated_at":"2024-07-02T16:36:15.000Z","phase":"Phase 2","brief_title":"ZR-CHOP in DLBCL With Specific Gene Abnormality","source_id_and_acronym":"NCT05290337","lead_sponsor":"Fudan University","biomarkers":" TP53 • MYC • MYD88 • CD79B","pipe":" | ","alterations":" TP53 mutation • NOTCH1 mutation • MYD88 mutation • CD79B mutation • CD79B mutation • MYC translocation","tags":["TP53 • MYC • MYD88 • CD79B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • NOTCH1 mutation • MYD88 mutation • CD79B mutation • CD79B mutation • MYC translocation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • Brukinsa (zanubrutinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 62","initiation":"Initiation: 01/04/2022","start_date":" 01/04/2022","primary_txt":" Primary completion: 01/04/2024","primary_completion_date":" 01/04/2024","study_txt":" Completion: 01/04/2026","study_completion_date":" 01/04/2026","last_update_posted":"2022-03-22"},{"id":"3e8d61ce-5436-4030-a690-3833bf9a750d","acronym":"","url":"https://clinicaltrials.gov/study/NCT01742988","created_at":"2021-01-18T07:38:21.868Z","updated_at":"2024-07-02T16:36:30.660Z","phase":"Phase 1","brief_title":"Study to Assess the Safety, Tolerability and Pharmacokinetics of Fimepinostat (CUDC-907) in Patients With Lymphoma","source_id_and_acronym":"NCT01742988","lead_sponsor":"Curis, Inc.","biomarkers":" MYC • BCL2 • BCL6 • CREBBP","pipe":" | ","alterations":" MYC overexpression • BCL6 rearrangement • MYC translocation • BCL2 rearrangement • BCL6 translocation • BCL2 translocation","tags":["MYC • BCL2 • BCL6 • CREBBP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MYC overexpression • BCL6 rearrangement • MYC translocation • BCL2 rearrangement • BCL6 translocation • BCL2 translocation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • Rituxan (rituximab) • fimepinostat (CUDC-907)"],"overall_status":"Completed","enrollment":" Enrollment 106","initiation":"Initiation: 12/01/2012","start_date":" 12/01/2012","primary_txt":" Primary completion: 10/09/2020","primary_completion_date":" 10/09/2020","study_txt":" Completion: 10/09/2020","study_completion_date":" 10/09/2020","last_update_posted":"2021-05-06"},{"id":"efb6b8cf-538e-4440-8fcd-91d55e221959","acronym":"","url":"https://clinicaltrials.gov/study/NCT02776891","created_at":"2021-01-18T13:37:01.006Z","updated_at":"2024-07-02T16:36:54.684Z","phase":"Phase 2","brief_title":"A Feasibility Study of Gallium-68 Citrate PET to Detect Aberrant MYC Proto-Oncogene, BHLH Transcription Factor (MYC) Protein Expression in Diffuse Large B-Cell Lymphoma","source_id_and_acronym":"NCT02776891","lead_sponsor":"University of California, San Francisco","biomarkers":" MYC • BCL2","pipe":" | ","alterations":" MYC overexpression • MYC translocation","tags":["MYC • BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MYC overexpression • MYC translocation"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 06/13/2016","start_date":" 06/13/2016","primary_txt":" Primary completion: 04/09/2018","primary_completion_date":" 04/09/2018","study_txt":" Completion: 04/09/2018","study_completion_date":" 04/09/2018","last_update_posted":"2019-10-10"}]